Protagonist Therapeutics, Inc. (PTGX)
PTGXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$135.90
+3.86 (+2.92%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $8.79bn
- P/E
- 28.8
- EPS, last 4 quarters
- $4.72
- Dividend yield
- –
- Day range
- –
- 52-week range
- $76.70 to $160.81
- Average volume
- 697.7k
- Previous close
- $132.04
Analysts
13 coveringStrong Buy13 buy, 0 hold, 0 sell
Targets a year out average $180.00, +32.5% from here
Earnings
next estimate $-0.3800Next report
Dec 2025
-30.2%
Mar 2026
+107.7%
Jun 2026
+8.5%
Sep 2026
+19.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $7.44m | $56.37m | $213.47m | $274.41m |
| Gross profit | $7.44m | $56.37m | $213.47m | $273.31m |
| Operating income | -$50.35m | -$3.65m | $158.77m | $218.33m |
| Net income | -$44.38m | $3.78m | $162.85m | $220.01m |
Last four quarters: revenue $551.69m, margin 62.0%, free cash flow $109.15m
News
8 latest- Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass EstimatesZacks · 4 days ago
- Niagen Bioscience (NAGE) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- Noteworthy ETF Outflows: IJT, PTGX, VSAT, TGTXBNK Invest · Oct 29, 2026
- Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks · Oct 29, 2026
- Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-TermZacks · Oct 29, 2026
- Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?Zacks · Oct 28, 2026
- J&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?Zacks · Oct 23, 2026
- Notable ETF Outflow Detected - SLYG, PTGX, RHP, TGTXBNK Invest · Oct 21, 2026
The company
Protagonist Therapeutics is a biopharmaceutical company built on a proprietary peptide technology platform that has now produced two FDA-approved, first-in-class medicines, generating royalties and milestones from global commercial partnerships with Johnson and Johnson and Takeda Pharmaceutical Company Limited. ICOTYDE (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 (IL-23) receptor. ICOTYDE was launched in the U.S. in March 2026 for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- protagonist-inc.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.